Jefferies analyst Akash Tewari upgraded BioNTech SE (BNTX – Research Report) to a Buy today and set a price target of $150.00. The company’s shares closed yesterday at $123.47. Tewari covers ...

TD Cowen analyst Yaron Werber maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $85.00. The company’s shares closed last Friday at $123.40.

The BioNTech SE ADR BNTX slid 2.69% to $112.51 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and the ...

BioNTech SE Sponsored ADR (BNTX) shares soared 5.8% in the last trading session to close at $105. The move was backed by solid volume with far more shares changing hands than in a normal session.

The Biontech logo can be seen on one of the company's warehouse buildings in Mainz. German vaccine manufacturer BioNTech is to sponsor Bundesliga side Mainz, the club announced on Friday ...

MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology ...

MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its ...

(MENAFN- GlobeNewsWire - Nasdaq) MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX,“BioNTech” or“the Company”) will present clinical trial data for selected assets from its ...

Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of ...